AR019305A1 - Hiv y tratamiento viral. - Google Patents

Hiv y tratamiento viral.

Info

Publication number
AR019305A1
AR019305A1 ARP990102384A ARP990102384A AR019305A1 AR 019305 A1 AR019305 A1 AR 019305A1 AR P990102384 A ARP990102384 A AR P990102384A AR P990102384 A ARP990102384 A AR P990102384A AR 019305 A1 AR019305 A1 AR 019305A1
Authority
AR
Argentina
Prior art keywords
hiv
virus
hydrogen
less
delay
Prior art date
Application number
ARP990102384A
Other languages
English (en)
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of AR019305A1 publication Critical patent/AR019305A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Una composicion farmacéutica que se puede usar para tratar infecciones virales, especialmente el HIV. La composicion comprende de 250mg a 6000 mg de underivado de benzimidazol de la formula 1 donde X es hidrogeno, halogeno, alquil de menos de 7 átomos de carbono, o alcoxi de menos de 7 átomos de carbono; n esun numero entero positivo de menos de 4; Y es hidrogeno, cloro, nitro, oxicloro, metilo, o etilo; y R es hidrogeno, o un grupo alquilo C1-8 y R2 es 4-tiazolily las sales de adicion orgánicas o inorgánicas farmacéuticamente aceptables de las mismas. El compuesto preferido es el tiabendazol. En la presente invencionse ha descubierto que los compuestos descriptos más arriba son utiles para la inhibicion del HIV y el tratamiento de la infeccion del HIV cuando se usa solo oen combinacion con otros agentes antivirales. Estas composiciones pueden prevenir la reproduccion del virus del HIV, crear una resistencia al virus en elpaciente y evitar o demorar la infeccion de las células con elvirus del HIV y demorar la reaparicion del virus en las células tratadas. Estas composicionesson tambien eficaces contra la hepatitis y herpes, influenza y rinovirus.
ARP990102384A 1998-05-19 1999-05-19 Hiv y tratamiento viral. AR019305A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8138498A 1998-05-19 1998-05-19

Publications (1)

Publication Number Publication Date
AR019305A1 true AR019305A1 (es) 2002-02-13

Family

ID=22163807

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990102384A AR019305A1 (es) 1998-05-19 1999-05-19 Hiv y tratamiento viral.

Country Status (19)

Country Link
US (1) US6245789B1 (es)
EP (1) EP1079831A1 (es)
JP (1) JP2002515432A (es)
KR (1) KR20010043709A (es)
CN (1) CN1301158A (es)
AR (1) AR019305A1 (es)
AU (1) AU4004299A (es)
BR (1) BR9911043A (es)
CA (1) CA2329877A1 (es)
CO (1) CO5050303A1 (es)
HU (1) HUP0103319A2 (es)
ID (1) ID27457A (es)
IL (1) IL139002A0 (es)
NO (1) NO20005839L (es)
PE (1) PE20000550A1 (es)
PL (1) PL344223A1 (es)
SK (1) SK17442000A3 (es)
TR (1) TR200003383T2 (es)
WO (1) WO1999059585A1 (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6479526B1 (en) 1995-04-12 2002-11-12 The Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of viruses and cancers
US6177460B1 (en) 1995-04-12 2001-01-23 The Procter & Gamble Company Method of treatment for cancer or viral infections
US6262093B1 (en) 1995-04-12 2001-07-17 The Proctor & Gamble Company Methods of treating cancer with benzimidazoles
US6265427B1 (en) 1995-06-07 2001-07-24 The Proctor & Gamble Company Pharmaceutical composition for the method of treating leukemia
US5770616A (en) 1995-06-07 1998-06-23 The Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of cancers
US6686391B2 (en) 1995-08-04 2004-02-03 University Of Arizona Foundation N-chlorophenylcarbamate and N-chlorophenylthiocarbamate compositions
US5900429A (en) 1997-01-28 1999-05-04 The Procter & Gamble Company Method for inhibiting the growth of cancers
US6506783B1 (en) * 1997-05-16 2003-01-14 The Procter & Gamble Company Cancer treatments and pharmaceutical compositions therefor
US6245789B1 (en) 1998-05-19 2001-06-12 The Procter & Gamble Company HIV and viral treatment
US6423734B1 (en) 1999-08-13 2002-07-23 The Procter & Gamble Company Method of preventing cancer
US6242461B1 (en) * 2000-01-25 2001-06-05 Pfizer Inc. Use of aryl substituted azabenzimidazoles in the treatment of HIV and AIDS related diseases
PE20020506A1 (es) 2000-08-22 2002-07-09 Glaxo Group Ltd Derivados de pirazol fusionados como inhibidores de la proteina cinasa
US6462062B1 (en) * 2000-09-26 2002-10-08 The Procter & Gamble Company Compounds and methods for use thereof in the treatment of cancer or viral infections
US6380232B1 (en) 2000-09-26 2002-04-30 The Procter & Gamble Company Benzimidazole urea derivatives, and pharmaceutical compositions and unit dosages thereof
US6608096B1 (en) 2000-09-26 2003-08-19 University Of Arizona Foundation Compounds and methods for use thereof in the treatment of cancer or viral infections
US6407105B1 (en) * 2000-09-26 2002-06-18 The Procter & Gamble Company Compounds and methods for use thereof in the treatment of cancer or viral infections
AU2002239395A1 (en) * 2000-11-01 2002-06-03 The Procter And Gamble Company Hiv treatment with benzimidazoles
US6919352B2 (en) 2000-12-15 2005-07-19 Smithkline Beecham Corporation Pyrazolopyridinyl pyridine and pyrimidine therapeutic compounds
JP2004515550A (ja) 2000-12-15 2004-05-27 グラクソ グループ リミテッド 治療用化合物
AU2002248531A1 (en) 2001-03-08 2002-09-24 Smithkline Beecham Corporation Pyrazolopyriadine derivatives
EP1372643A1 (en) 2001-03-30 2004-01-02 Smithkline Beecham Corporation Pyrazolopyridines, process for their preparation and use as therapeutic compounds
ATE332301T1 (de) 2001-04-10 2006-07-15 Smithkline Beecham Corp Antivirale pyrazolopyridin verbindungen
ES2242028T3 (es) 2001-04-27 2005-11-01 Smithkline Beecham Corporation Derivados de pirazolo(1,5-a)piridina.
CN1518550A (zh) 2001-06-21 2004-08-04 ʷ��˿�������ȳ�ķ���޹�˾ 用于预防和治疗疱疹病毒感染的咪唑并[1,2-a]吡啶衍生物
EP1432712B1 (en) 2001-10-05 2006-05-17 SmithKline Beecham Corporation Imidazo-pyridine derivatives for use in the treatment of herpes viral infection
AU2002357740A1 (en) 2001-12-11 2003-06-23 Smithkline Beecham Corporation Pyrazolo-pyridine derivatives as antiherpes agents
US7022712B2 (en) * 2002-03-26 2006-04-04 Arizona Board Of Regents On Behalf Of The University Of Arizona Solubilization of weak bases
WO2004033454A1 (en) 2002-10-03 2004-04-22 Smithkline Beecham Corporation Therapeutic compounds based on pyrazolopyridine derivatives
AU2003900064A0 (en) * 2003-01-09 2003-01-23 Penam Investments Pty. Ltd. A method of treatment or prophylaxis of viral infection.
JP2005060362A (ja) * 2003-07-28 2005-03-10 Shionogi & Co Ltd セスキテルペン誘導体を含有する抗ＨＩＶ剤、抗ＢＶＤＶ剤、抗ＨＣＶ剤又は抗ＣｏＶ剤
EP2251010A1 (en) 2009-05-08 2010-11-17 Sygnis Bioscience GmbH & Co. KG Use of thiabendazole and derivatives thereof for the therapy of neurological conditions
CA2905375A1 (en) * 2013-03-15 2014-09-18 Camas Incorporated Methods and compositions for reducing microorganisms in the oropharynx, nasopharynx and oral cavities
FR3057865A1 (fr) * 2016-10-21 2018-04-27 Laboratoire Michel Iderne Composition chimique
TW201936193A (zh) * 2017-12-05 2019-09-16 愛爾蘭商健生科學愛爾蘭無限公司 使用組合產品治療ｒｓｖ
KR102342313B1 (ko) * 2021-08-27 2021-12-24 (주)바이오메트릭스 테크놀로지 벤지미다졸-탄수화물 결합체 화합물을 포함하는 미셀, 이의 제조방법, 이의 항암제 또는 항바이러스제로서의 용도

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3010968A (en) 1959-11-25 1961-11-28 Du Pont Process for manufacture of certain alkyl esters of benzimidazole carbamic acids
NL134354C (es) 1963-05-23
US3499761A (en) 1964-07-20 1970-03-10 Gaf Corp Silver halide emulsions containing alkyl esters of benzimidazole carbamic acid antifogging agents
US3541213A (en) 1966-05-06 1970-11-17 Du Pont Fungicidal and mite ovicidal substituted 2-aminobenzimidazoles
US3881014A (en) 1968-11-05 1975-04-29 Bayer Ag N-tritylimidazoles for treating fungal infections
BE759337A (fr) 1969-11-24 1971-05-24 Lilly Co Eli Benzimidazol (2,1-b)-quinazolin (6h) ones qui sont des immuno-depresseurs, et nouvelles benzimidazo (2,1-b) quinazolin-12-(6h) ones
US3956262A (en) 1970-12-09 1976-05-11 Beecham Group Limited Triazenoimidazoles
US3738995A (en) 1971-05-14 1973-06-12 Du Pont Solvent process for the preparation of 1 - carbamoyl-substituted 2 - benzimidazolecarbamates
FR2155888A1 (en) 1971-10-13 1973-05-25 Agot Aime Solid anthelmintic composn - for more economical treatment of ruminants
US4046906A (en) 1973-04-21 1977-09-06 Hoechst Aktiengesellschaft Salts of alkyl 2-benzimidazole-carbamate
HU193951B (en) 1985-03-11 1987-12-28 Richter Gedeon Vegyeszet Process for producing new sulfur-containing 5-substituted benzimidazol derivatives and pharmaceutical compositions containing them
US4731366A (en) 1986-08-05 1988-03-15 Harbor Branch Oceanographic Institution, Inc. Discorhabdin compositions and their methods of use
GB2210875B (en) 1987-10-09 1991-05-29 Farmos Oy Aromatase inhibiting 4(5)-imidazoles
US5329012A (en) 1987-10-29 1994-07-12 The Research Foundation Of State University Of New York Bis(acyloxmethyl)imidazole compounds
US5114951A (en) 1989-04-11 1992-05-19 Burroughs Wellcome Company Agents for combating multiple drug resistance
US5149527A (en) 1990-09-18 1992-09-22 Oncotech, Inc. Immunopotentiating protocol for chemotherapy-responsive tumors
US5364875A (en) 1992-05-11 1994-11-15 The Du Pont Merck Pharmaceutical Company Imidazoles linked to bicyclic heterocyclic groups for the treatment of atherosclerosis
US5310748A (en) 1992-05-11 1994-05-10 The Du Pont Merck Pharmaceutical Company Imidazoles for the treatment of atherosclerosis
US5290801A (en) 1992-05-29 1994-03-01 The Du Pont Merck Pharmaceutical Company Benzimidazoles for the treatment of atherosclerosis
JPH08500112A (ja) 1992-08-12 1996-01-09 ジ・アップジョン・カンパニー タキソールと組み合わせるプロテインキナーゼ阻害剤および関連化合物
RO118000B1 (ro) 1993-03-31 2002-12-30 Merck & Co Inc Metoda pentru tratamentul sida, prevenirea si tratamentul infectiei cu hiv sau inhibarea proteazei hiv si compozitie farmaceutica pentru aplicarea metodei
US5434163A (en) 1993-05-14 1995-07-18 The Medical College Of Pennsylvania Treatment of Cryptococcus neoformans infection
JP3213471B2 (ja) 1994-04-13 2001-10-02 ポーラ化成工業株式会社 薬効成分含有リポソーム製剤の製造方法
ZA962880B (en) 1995-04-12 1997-03-17 Procter & Gamble A pharmaceutical composition for inhibiting the growth of viruses and cancers
NZ305784A (en) 1995-04-12 2001-03-30 Procter & Gamble Benzimidazole containing medicaments for treating cancers, tumors and viral infections
US5656615A (en) 1995-04-12 1997-08-12 The Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of cancers and viruses in mammals
US5665713A (en) 1995-04-12 1997-09-09 Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of viruses and cancers
ZA962879B (en) 1995-04-12 1997-03-17 Procter & Gamble A pharmaceutical composition for inhibiting the growth of viruses and cancers
BR9604973A (pt) 1995-04-12 1998-06-09 Procter & Gamble Uma composição farmacêutica contendo carbamatos de n-cloro fenila e tiocarbamatos de n-cloro fenila para inibição de crescimento de vírus e cânceres
US5629341A (en) 1995-04-12 1997-05-13 The Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of viruses and cancers
US5770616A (en) 1995-06-07 1998-06-23 The Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of cancers
MX9707809A (es) 1995-06-07 1998-01-31 Procter & Gamble Una composicion farmaceutica que contiene bencimidazol para inhibir el crecimiento de canceres.
AU717382B2 (en) 1995-06-07 2000-03-23 Procter & Gamble Company, The Use of benzimidazoles for the manufacture of a medicament for the treatment of leukemia
US5665751A (en) 1995-06-07 1997-09-09 The Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of cancers
US6200992B1 (en) 1995-06-07 2001-03-13 The Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of cancers
WO1997005870A2 (en) 1995-08-03 1997-02-20 The Procter & Gamble Company Use of griseofulvin for inhibiting the growth of cancers
CA2229024A1 (en) 1995-08-04 1997-02-20 The Procter & Gamble Company Use of fluconazole for inhibiting the growth of cancers
US5908855A (en) 1996-07-16 1999-06-01 The Procter & Gamble Company Compositions for treating viral infections
US5900429A (en) 1997-01-28 1999-05-04 The Procter & Gamble Company Method for inhibiting the growth of cancers
US6506783B1 (en) 1997-05-16 2003-01-14 The Procter & Gamble Company Cancer treatments and pharmaceutical compositions therefor
PE11499A1 (es) 1997-05-16 1999-03-01 Procter & Gamble Tratamiento del hiv y cancer
US6245789B1 (en) 1998-05-19 2001-06-12 The Procter & Gamble Company HIV and viral treatment

Also Published As

Publication number Publication date
BR9911043A (pt) 2001-02-13
NO20005839D0 (no) 2000-11-17
IL139002A0 (en) 2001-11-25
SK17442000A3 (sk) 2001-08-06
PL344223A1 (en) 2001-10-08
CN1301158A (zh) 2001-06-27
CO5050303A1 (es) 2001-06-27
WO1999059585A1 (en) 1999-11-25
CA2329877A1 (en) 1999-11-25
EP1079831A1 (en) 2001-03-07
NO20005839L (no) 2001-01-16
HUP0103319A2 (hu) 2002-05-29
AU4004299A (en) 1999-12-06
JP2002515432A (ja) 2002-05-28
PE20000550A1 (es) 2000-06-29
US6245789B1 (en) 2001-06-12
TR200003383T2 (tr) 2001-03-21
KR20010043709A (ko) 2001-05-25
ID27457A (id) 2001-04-12

Similar Documents

Publication Publication Date Title
AR019305A1 (es) Hiv y tratamiento viral.
CO5160294A1 (es) Composicion farmaceutica que inhibe o detiene el crecimiento de virus en animales particularmente mamiferos sarrollo de virus en animales y composiciones farmaceuticas que los contienen
BR0312271A (pt) compostos, composições e seus usos para o tratamento de infecções por flaviviridae
MXPA04012779A (es) Profarmacos de 2'- y 3'-nucleosido para tratar infecciones por flaviviridae.
AR012964A1 (es) Compuetos derivados de bencimidazol, composiciones farmaceuticas que los contienen y su uso en la manufactura de medicamentos para tratar infeccionesvirales
BRPI0213522C1 (pt) compostos derivados de hidroxipirimidinona, composição farmacêutica, e, uso de um composto
HUP0001170A2 (hu) Hatóanyagként enzimidazol-2-karbamát-származékokat tartalmazó, vírusfertőzések és rák kezelésére alkalmas gyógyszerkészítmények
CO5200778A1 (es) Composicion farmaceutica que comprende una cantidad terapeuticamente efectiva de b enzimidazol, administrada para prevenir y tratar el cancer e inhibir la metastasis
TW427887B (en) Pharmaceutical composition comprising a benzimidazole derivative for treating viral infections
EA200600582A1 (ru) Способы и композиции для лечения вирусного гепатита с
EA200600227A1 (ru) Замещённые арилтиомочевины, применимые в качестве ингибиторов репликации вирусов
AR018706A1 (es) Uso de una composicion farmaceutica para tratamiento de infecciones virales
HUP9900901A2 (hu) N-(Klór-fenil)-karbamátokat és N-(klór-fenil)-tiokarbamátokat tartalmazó, rákellenes és vírusok szaporodását gátló gyógyszerkészítmény
CA2373833A1 (en) Medicinal compositions for preventing or treating viral myocarditis
AR003137A1 (es) Una composicion farmaceutica para tratar la leucemia
BR0314695A (pt) Composto, processo para preparar um composto, processo para preparar um estereoisÈmero de um composto, composição para o tratamento de doenças virais, e, composição para o tratamento da hepatite b
CO5080752A1 (es) INHIBIDORES DEL FACTOR DE TRANSCRIPCION NF-kB
PE61699A1 (es) Composicion farmaceutica de lamivudina
KR880007462A (ko) 빈뇨치료용 프로피오페논 유도체
WO2002041891A3 (en) Hiv treatment with benzimidazoles
ATE192926T1 (de) Flavopereirine enthaltende zusammensetzung und ihre anwendung in der behandlung gegen hiv-viren
AR016386A1 (es) D- o l-lixofuranosil benzimidazoles composicion que los contiene, procedimiento para su preparacion y su uso para la manufactura de un medicamento
KR910021407A (ko) 바이러스에 의해 유발된 질환을 치료하기 위한 벤질포스폰산 유도체의 용도
AR018707A1 (es) Composicion farmaceutica para tratar infecciones virales
KR970704441A (ko) 사람 면역결핍증 바이러스 프로테아제 억제제 배합물(HIV Protease inhibitor combination)